Japan relies almost entirely on China for the APIs of β-lactam antibiotics. These drugs are essential for treating infectious diseases…
HOME > REGULATORY
REGULATORY
- Ishiba Elected as New LDP Leader, Hopes Are High for Medical and Pharma Policies
September 30, 2024
- MHLW Set to Redefine “Vaccines of High Development Priority” in New Plan
September 27, 2024
- MHLW to Publish Info Necessary for Driving Biosimilar Switches in FY2025
September 27, 2024
- Kisunla Subject to Prior Pricing Review as It Follows Leqembi’s Footsteps
September 26, 2024
- Off-Year Debate “Won’t Progress” without Industry’s Behavioral Change: JMA Rep
September 26, 2024
- MHLW Panel Puts a Hold on Proposed Use of Abortion Pill at Clinics Without Beds
September 26, 2024
- Japan Approves Lilly’s Kisunla, Eisai’s ALS Med, Gilead’s Trodelvy, and Lots More
September 25, 2024
- NIBIOHN, Institut Pasteur Link Arms in Drug, Vaccine Research
September 24, 2024
- More Pregnant Cases Reported for COVID Meds, Panel Urges Greater Caution
September 24, 2024
- Ultragenyx’s Gene Therapy in Line for Orphan Tag in Japan
September 24, 2024
- Orphan Status Granted to Sanofi’s Venglustat and More in Japan
September 24, 2024
- Japan Pulls Sakigake Tags from Olumiant, Xevinapant
September 24, 2024
- Panelists See Legal Issue over Providers’ Refusal of People Vaccinated with Replicon Shot
September 20, 2024
- MHLW to Update Decade-Old Generic Roadmap, Add Blueprint for Biosimilars
September 20, 2024
- Japan Panel OKs 5 COVID Vaccines for NIP Use from October
September 20, 2024
- Puberulic Acid Determined as Cause of “Beni-Koji” Health Damages
September 19, 2024
- MHLW Working Group Gets into Details of Proposed Drug Supply Info System
September 18, 2024
- “Kobe Model” Offers Unique Subsidy to Diagnose Dementia, Test Eligibility for Lecanemab
September 18, 2024
- 9 LDP Leader Candidates Showcase Pharma Agendas in Campaign
September 17, 2024
- FY2025 Budget Request Would Add 7 PMDA Reviewers for Startup Consultations
September 13, 2024
ページ
Your company’s employer brand is your reputation as an employer and is crucial in attracting top talent. Some reputations are just not good; they may or not be deserved. That is just the perception in the market. Years ago there…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s key reimbursement policy panel on December 25 approved an outline of the FY2025 drug price revision, finalizing plans to…
For the first time in many years, Japan appeared to have pivoted to a pro-innovation path with the FY2024 drug pricing reform. All eyes were apparently on this course change as seen in this year’s most-read story list, though the…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
The Ministry of Health, Labor and Welfare (MHLW) posted the final report compiled by its pharmaceutical regulation panel on its website on April 24, providing cases of drugs that could be exempted from all-case post marketing surveillance (PMS).The MHLW plans…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…